Inmunómica traslacional en neoplasias hematológicas
University of Texas Southwestern Medical Center
Dallas, Estados UnidosPublicacións en colaboración con investigadores/as de University of Texas Southwestern Medical Center (5)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
2021
-
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Leukemia, Vol. 35, Núm. 6, pp. 1722-1731
2016
-
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39